These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7814484)

  • 1. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.
    Keitel WA; Couch RB; Cate TR; Hess KR; Baxter B; Quarles JM; Atmar RL; Six HR
    J Clin Microbiol; 1994 Oct; 32(10):2468-73. PubMed ID: 7814484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.
    Keitel WA; Cate TR; Atmar RL; Turner CS; Nino D; Dukes CM; Six HR; Couch RB
    Clin Diagn Lab Immunol; 1996 Sep; 3(5):507-10. PubMed ID: 8877126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.
    Powers DC; Sears SD; Murphy BR; Thumar B; Clements ML
    J Clin Microbiol; 1989 Dec; 27(12):2666-71. PubMed ID: 2592535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature.
    Palache AM; Beyer WE; Lüchters G; Völker R; Sprenger MJ; Masurel N
    Vaccine; 1993; 11(9):892-908. PubMed ID: 8212834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.
    Clements ML; Murphy BR
    J Clin Microbiol; 1986 Jan; 23(1):66-72. PubMed ID: 3700610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.
    Treanor JJ; Betts RF; Smith GE; Anderson EL; Hackett CS; Wilkinson BE; Belshe RB; Powers DC
    J Infect Dis; 1996 Jun; 173(6):1467-70. PubMed ID: 8648221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
    Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
    J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.
    Halperin SA; Smith B; Clarke K; Treanor J; Mabrouk T; Germain M
    Hum Vaccin; 2005; 1(1):37-42. PubMed ID: 17038827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.
    Murphy BR; Nelson DL; Wright PF; Tierney EL; Phelan MA; Chanock RM
    Infect Immun; 1982 Jun; 36(3):1102-8. PubMed ID: 7095844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.
    Gorse GJ; Otto EE; Powers DC; Chambers GW; Eickhoff CS; Newman FK
    J Infect Dis; 1996 Feb; 173(2):285-90. PubMed ID: 8568287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak.
    Gravenstein S; Drinka P; Duthie EH; Miller BA; Brown CS; Hensley M; Circo R; Langer E; Ershler WB
    J Am Geriatr Soc; 1994 Mar; 42(3):245-51. PubMed ID: 8120307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
    J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.
    Goodeve A; Potter CW; Clark A; Jennings R; Schild GC; Yetts R
    J Hyg (Lond); 1983 Feb; 90(1):107-15. PubMed ID: 6822725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.